# A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

> **NCT06369285** · PHASE2 · RECRUITING · sponsor: **Puma Biotechnology, Inc.** · enrollment: 150 (estimated)

## Conditions studied

- Hormone Receptor Positive HER-2 Negative Breast Cancer
- Metastatic Breast Cancer
- Recurrent Breast Cancer

## Interventions

- **DRUG:** Alisertib
- **DRUG:** Endocrine therapy

## Key facts

- **NCT ID:** NCT06369285
- **Lead sponsor:** Puma Biotechnology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-19
- **Primary completion:** 2027-06-30
- **Final completion:** 2028-12-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06369285

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06369285, "A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-21 from https://api.ai-analytics.org/clinical/NCT06369285. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*